Debra Reisenthel

Chief Executive Officer

Debra joined Palo Alto Health Sciences (PAHS) as President and CEO in February 2013.  She brings a unique blend of experience to her role, having both successfully led the commercialization of early stage ventures and having expertise in respiratory physiology. Previously Debra was President, CEO and Board member of Novasys Medical from 2001-2010 (acquired by Verathon Medical in 2012), where she led the development, launch and commercialization of the Renessa treatment for female stress urinary incontinence. 

While at Novasys, Debra was awarded the “Most Promising New Product” for the Renessa system at the 2009 Phoenix Medical Device and Diagnostic CEO Conference, was the subject of a case study by Harvard Business School for Novasys Medical’s reimbursement strategy, was recognized by Stanford Business School in a video Case Study "Managing Through a Crisis", and was the recipient of Adaptive Business Leaders 2010 “Leadership in Innovation Award”. She also raised significant capital from leading healthcare venture capital investors for Novasys Medical.

Prior to Novasys, Debra was Vice President and General Manager at Tyco Inc. (Mallinckrodt, Nellcor Puritan Bennett, Nellcor).  Early in her career Debra was Assistant Director of Respiratory Care at Loyola University Medical Center in Chicago.  Debra holds a B.A. in Applied Behavioral Sciences, an MBA and R.R.T credentials. 


Simon Thomas
Chief Operating Officer

Simon joined Palo Alto Health Sciences in December 2013 with significant broad-based experience in the medical device field.  Simon has successfully developed and commercialized numerous innovative technologies, from concept stage through established commercialization.  Most recently Simon was Sr. VP Operations and Engineering at Home Dialysis Plus (HD+), focused on a next-generation hemodialysis system for home use. 

Prior to HD+, he served as VP of R&D, RA/QA and Operations at Novasys Medical where he was responsible for the development, launch and manufacturing of the Renessa treatment.  He was also Sr. Director of R&D at Nellcor, where he led the development and regulatory filing (PMA) for the N-400 Fetal Pulse Oximeter. He was VP of Engineering at GE/Marquette Medical Systems (Corometrics) focused on fetal and newborn monitoring systems, including home-based products.   At Novametrix, Simon developed new physiologic gas monitoring technologies (including EtCO2 and pulse oximetry) for use on adults and neonates.

Simon holds numerous patents and a BS with Honors in Physics from Imperial College of Science and Technology in London.


Robert Cuyler, Ph.D.

Chief Clinical Officer


Robert has over 30 years of clinical and business development experience in the mental health arena.  He previously was the interim CEO of JSA Tele-psychiatry and Senior Vice President of Diamond Healthcare. Robert has over 10 years’ experience designing and implementing telemedicine programs throughout the United States. He is also a co-author of"Implementing Telemedicine" and chapters "The Role of Tele-psychiatry" in Behavioral Emergencies for the Emergency Physician, Cambridge Press & "Telepsychiatry and e-Mental Health" in Handbook of Community Psychiatry, Springer Science.

Robert completed his undergraduate degree in Psychology at the University of New Orleans before completing his M.A., Ph.D. at Louisiana State University, majoring in Clinical Psychology with a Minor in Behavioral Neurology. He received his Post-Doctoral Fellowship in Psychology from the Menninger Foundation, Topeka, Kansas. 

He continues to run a highly successful private practice in Bellaire, TX.


Chris Jaquis
Vice President, Business Development

Chris is a strategic growth expert with over 20 years of experience partnering with Payers and providers within the behavioral healthcare industry.  He most recently served as the VP of Development at Townsend Addiction Treatment Centers (Lafayette, LA) where he grew in-network Payer relationships which played a significant role in Townsend's acquisition by American Addiction Centers.

Before joining Townsend, Chris served as Strategic Accounts Director for Breakthrough Behavioral, a leader in tele-behavioral health delivery. While at Breakthrough, Chris was responsible for the execution of the company’s sales strategy; Breakthrough's success led to acquisition by MDLive in November of 2014. At CRC Health Inc., Chris held various senior leadership positions over 14 years. CRC became the largest for-profit Drug and Alcohol Treatment System in the U.S.

Chris is a graduate of Mansfield University.